iBio is a preclinical-stage biotech company using AI to discover and develop antibody therapies for obesity and cardiometabolic diseases. The company's core focus is developing biologics designed to address the limitations of GLP-1 receptor agonists like Ozempic and Wegovy — specifically, muscle loss during weight loss treatment, weight regain after stopping GLP-1s, and tolerability issues. iBio's two lead programs are IBIO-600, an anti-myostatin antibody designed to prevent muscle loss during GLP-1 treatment, currently in IND-enabling studies, and IBIO-610, an Activin E antibody designed for fat-selective weight loss, currently at development candidate stage. iBio also holds a secondary pipeline of immuno-oncology antibodies that it is seeking to out-license rather than develop internally. The company's central asset is its proprietary AI drug discovery platform, which includes Epitope Steering (a patented AI engine that directs antibodies to specific protein regions), StableHu (a generative AI optimization tool), and specialty tools for bispecific and conditionally activated antibodies. iBio licenses this platform to partners in exchange for fees, milestones, and royalties, and retains options to license back resulting drug candidates. iBio has no approved products, generates no product revenue, and is funded entirely through equity raises. The company's first human clinical trial is targeted for late FY2026 or early FY2027.